EUVIMEDEUVIMED entdecken
Open Access · CC0

Prospective follow-up of New York City residents with e-cigarette, or vaping product use-associated lung injury—2020–2021

Kathryn M Tannert Niang iD, Aviva B Grasso iD, Indira Debchoudhury, Dena Bushman, John P Jasek, Monique A Fairclough, Katherine R Van Oss, Shadi Chamany, Kendall D LaSane, Sharraine M Franklin, Achala K Talati iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0304918 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Kathryn M Tannert Niang und 10 weiteren Autor:innen. Beteiligte Einrichtung: New York City Department of Health and Mental Hygiene, Center for Health Equity and Community Wellness, New York, New York, United States of America. Hauptthemen laut MEDLINE: Vaping, Electronic Nicotine Delivery Systems, Lung Injury. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A multistate outbreak of e-cigarette, or vaping, product use-associated lung injury (EVALI) occurred in 2019. Because of EVALI’s novelty and severity, the New York City (NYC) Department of Health and Mental Hygiene (DOHMH) prospectively assessed sequelae among NYC residents who received an EVALI diagnosis in 2019.

Methods

Using existing NYC EVALI surveillance data, DOHMH attempted contact with all living residents who received an EVALI diagnosis in 2019 and conducted 3 waves of telephone interviews during April 2020–March 2021. Interview questions were adapted from the Centers for Disease Control and Prevention’s EVALI case report form and validated surveys. Baseline differences between respondents and nonrespondents were assessed with Chi-square and Fisher’s exact tests; clinical and behavioral characteristics and open-ended responses were summarized.

Results

In 2019, 53 NYC residents received an EVALI diagnosis; 33 (67%), 14 (29%), and 18 (37%) of 49 living residents participated in the first, second, and third interviews, respectively. Interviews occurred after outpatient diagnosis (6%) or hospital discharge (94%), at a median of 8, 11, and 17 months for each wave. Respondents (N = 33) and nonrespondents (N = 16) did not differ by sex, age, hospitalization status or length. Respondents were mostly male (70%), had a median age of 23 years (range: 16–63 years), and all reported using vaping or e-cigarette products (vaping) with tetrahydrocannabinol (88%), nicotine (49%), or cannabidiol (9%) before diagnosis. Respiratory (first and second interviews) and gastrointestinal (third interviews) symptoms were most commonly reported. Sixteen respondents (49%) reported any new diagnosis during follow-up. Fifteen to 29% of respondents reported vaping at each interview; 58%–93% reported recent non-vaped cannabinoid use.

Conclusion

NYC residents with EVALI reported symptoms throughout the follow-up period, and approximately half reported newly diagnosed health conditions. Further studies are needed to understand EVALI’s relationship with symptoms and health conditions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

VapingElectronic Nicotine Delivery SystemsLung InjuryHumansNew York CityMaleFemaleAdultMiddle AgedProspective StudiesFollow-Up StudiesYoung AdultAdolescent

Autor:innen und Institutionen

  • New York City Department of Health and Mental Hygiene, Center for Health Equity and Community Wellness, New York, New York, United States of America.
  • Division of Scientific Education and Professional Development, CDC, Epidemic Intelligence Service, Atlanta, Georgia, United States of America.
  • Corewell Health, Women's Health & Wellness Center, Grand Rapids, Michigan, United States of America.
  • Department of Health Policy and Management, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, United States of America.
  • New York City Department of Health and Mental Hygiene, Center for Health Equity and Community Wellness, New York, New York, United States of America (Retired).

ORCID-Profile: Kathryn M Tannert Niang, Aviva B Grasso, Achala K Talati

Zitieren

APA

Tannert Niang, K. M., Grasso, A. B., Debchoudhury, I., Bushman, D., Jasek, J. P., Fairclough, M. A., Van Oss, K. R., Chamany, S., LaSane, K. D., Franklin, S. M., & Talati, A. K. (2025). Prospective follow-up of New York City residents with e-cigarette, or vaping product use-associated lung injury—2020–2021. PLOS One. https://doi.org/10.1371/journal.pone.0304918

Vancouver

Tannert Niang KM, Grasso AB, Debchoudhury I, Bushman D, Jasek JP, Fairclough MA, et al. Prospective follow-up of New York City residents with e-cigarette, or vaping product use-associated lung injury—2020–2021. PLOS One. 2025. doi:10.1371/journal.pone.0304918

BibTeX
@article{TannertNiang2025,
  author = {Tannert Niang, Kathryn M and Grasso, Aviva B and Debchoudhury, Indira and Bushman, Dena and Jasek, John P and Fairclough, Monique A and Van Oss, Katherine R and Chamany, Shadi and LaSane, Kendall D and Franklin, Sharraine M and Talati, Achala K},
  title = {Prospective follow-up of New York City residents with e-cigarette, or vaping product use-associated lung injury—2020–2021},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0304918}
}
Kostenlos starten →